http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2546677-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8925b769d645f9ff06af9f4b189f6a99 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-665 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-645 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2004-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c2fbd86d2a6662136d3dcb066b83b48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_778e3f534499f83221fb1dd42137b13c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fd32f8ff799977cf6f0766334ac6144 |
| publicationDate | 2005-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2546677-A1 |
| titleOfInvention | Pharmaceutical formulations for the sustained release of interferons and therapeutic applications thereof |
| abstract | The present invention relates to novel pharmaceutical formulations for base of stable and fluid aqueous colloidal suspensions for release prolonged IFN-interferon (and one or more other active ingredient (s) possible), as well as the applications, in particular the therapeutic ones, of these formulations. The purpose of the invention is to propose a formulation pharmaceutical formulation for the sustained release of interferon (s) (and one or several other possible active principle (s), allowing after injection parenterally significantly increase the duration of interferons, while decreasing the peak plasma concentration of this IFN, said formulation must also be stable at the conservation and, in addition, biocompatible, biodegradable, non-toxic, immunogenic and well tolerated locally. The formulation according to the invention is an aqueous colloidal suspension of low viscosity, of particles submicron biodegradable PO polymer, water-soluble and carrier of hydrophobic groups (GH), which particles are associated with non-covalent with at least one interferon (and one or more possible active principle (s)) and forming a gelled deposit on the site injection, this gelation being caused by a protein present in the physiological medium. |
| priorityDate | 2003-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 218.